Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD
NCT ID: NCT01819415
Last Updated: 2017-04-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2011-02-28
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degeneration
NCT01653184
Age-Related Eye Disease Study (AREDS)
NCT00000145
Omega-3-fatty Acids on Age-related Macular
NCT01258335
Study of the Effects of Supplements on Eye Disease in Participants From the Age-Related Eye Disease Study
NCT01915238
Age-Related Eye Disease Study 2 (AREDS2)
NCT00345176
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Naive
Patients starting on intravitreal anti-VEGF treatment, not receiving Omega-3 supplements. They serve as wet-AMD controls.
No interventions assigned to this group
Anti-VEGF plus AREDS-1 supplementation.
Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-1 plus Lutein supplementation formula.
Anti-VEGF plus AREDS-1
Patients receiving intravitreal anti-VEGF and AREDS-1 supplementation plus Lutein, without Omega-3.
Anti-VEGF plus AREDS-2
Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-2 supplementation formula, that includes Omega-3 metabolites (DHA and EPA).
Anti-VEGF plus AREDS-2
Omega-3 metabolites supplementation
Control
Patients undergoing vitrectomy surgery for epiretinal membrane or macular hole had their vitreous samples to serve as controls.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anti-VEGF plus AREDS-2
Omega-3 metabolites supplementation
Anti-VEGF plus AREDS-1
Patients receiving intravitreal anti-VEGF and AREDS-1 supplementation plus Lutein, without Omega-3.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed exudation on SD-OCT.
Exclusion Criteria
* Disciform scar.
* Smokers.
* Morbid obesity.
* Patients undergoing other forms of treatment for wet AMD.
50 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fonds de recherche en ophtalmologie de l'Université de Montréal
OTHER
Foundation Fighting Blindness
OTHER
Retina Foundation of Canada
UNKNOWN
Insight Instruments
UNKNOWN
Synergetics Inc
UNKNOWN
Novartis
INDUSTRY
Maisonneuve-Rosemont Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Flavio Rezende
Chief of Retina Service, Department of Ophthalmology, University of Montreal
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Flavio A Rezende, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Maisonneuve-Rosemont Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maisonneuve Rosemont Hospital
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HMR-10059
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.